MTL-CEBPA
MTL-CEPBA is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEPBA has anti-inflammatory and anti-cancer activity.
For research use only. We do not sell to patients.
- CAS No.: 2862057-05-2
- Molecular Weight:13464.27
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
MTL-CEBPA does not significantly change total human CD45+ cells, and T lymphocytes (hCD4+ and hCD8+ T cell subsets) in PB. However, MTL-CEBPA treatment increases CD16+ granulocytes and CD14+ monocytes in peripheral blood (PB)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MTL-CEBPA restores LPS-induced (12.5 μg; ip; single dose) reduction of C/EBPα and downregulates several genes associated with immune and inflammatory response in an LPS-stimulated humanized NSG model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2862057-05-2
-
Appearance Solid
-
Molecular Weight 13464.27
-
Color White to off-white
-
SMILES
[MTL-CEBPA]
-
Synonyms
CEBPA-51
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Jiehua Zhou, et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol Ther. 2019 May 8;27(5):999-1016. [Content Brief]
[2]. Reebye V, Huang KW, Lin V, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216-3228. [Content Brief]
[3]. Combination therapies comprising C/EBPα-targeted short-activating RNA (saRNA). WO2022229644A1
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz